Profile data is unavailable for this security.
About the company
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
- Revenue in USD (TTM)4.02bn
- Net income in USD-83.48m
- Incorporated1994
- Employees18.60k
- LocationCharles River Laboratories International Inc251 Ballardvale StWILMINGTON 01887United StatesUSA
- Phone+1 (781) 222-6000
- Fax+1 (978) 988-5665
- Websitehttps://www.criver.com/
More ▼
Mergers & acquisitions
| Acquired company | CRL:NYQ since announced | Transaction value |
|---|---|---|
| Pathoquest SAS | -14.35% | -- |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | 43.73m | -295.12m | 6.06bn | 225.00 | -- | 5.76 | -- | 138.55 | -3.59 | -3.59 | 0.5332 | 13.19 | 0.0409 | -- | 66.41 | 232,627.70 | -27.62 | -23.82 | -29.53 | -27.88 | -- | -- | -674.81 | -240.35 | -- | -- | 0.0039 | -- | -40.11 | 74.20 | -52.32 | -- | 89.02 | -- |
| Cogent Biosciences Inc | 0.00 | -214.77m | 6.26bn | 205.00 | -- | 25.66 | -- | -- | -1.77 | -1.77 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -72.69 | -57.20 | -84.75 | -63.62 | -- | -- | -- | -9,345.59 | -- | -- | 0.1276 | -- | -- | -- | -30.01 | -- | 76.98 | -- |
| Belite Bio Inc (ADR) | 0.00 | -49.38m | 6.69bn | 25.00 | -- | 38.92 | -- | -- | -1.55 | -1.55 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -36.85 | -- | -36.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.26 | -- | -- | -- |
| Cytokinetics, Inc. | 87.21m | -751.94m | 7.37bn | 498.00 | -- | -- | -- | 84.45 | -6.31 | -6.31 | 0.7328 | -4.27 | 0.0607 | -- | 85.00 | 175,122.50 | -52.35 | -45.50 | -57.39 | -50.38 | -- | -- | -862.21 | -748.37 | -- | -14.45 | 1.96 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
| Vaxcyte Inc | 0.00 | -657.20m | 7.60bn | 414.00 | -- | 2.42 | -- | -- | -4.84 | -4.84 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -19.53 | -26.00 | -20.51 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Nuvalent Inc | 0.00 | -381.44m | 7.79bn | 218.00 | -- | 8.63 | -- | -- | -5.32 | -5.32 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -35.18 | -25.32 | -37.61 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Praxis Precision Medicines Inc | 7.46m | -273.04m | 8.38bn | 116.00 | -- | 18.83 | -- | 1,122.36 | -12.90 | -12.90 | 0.3533 | 16.23 | 0.0184 | -- | -- | 64,336.21 | -67.20 | -70.37 | -75.12 | -79.85 | -- | -- | -3,658.53 | -6,809.15 | -- | -- | 0.00 | -- | 249.53 | -- | -48.30 | -- | -- | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -83.48m | 9.04bn | 18.60k | -- | 2.65 | 26.02 | 2.25 | -1.56 | -1.56 | 80.18 | 69.20 | 0.5186 | 8.23 | 5.41 | 216,328.20 | -1.03 | 5.12 | -1.20 | 6.01 | 34.68 | 36.56 | -1.98 | 9.47 | 1.10 | 3.18 | 0.388 | 0.00 | -1.92 | 9.09 | -97.83 | -47.25 | 10.64 | -- |
| Arrowhead Pharmaceuticals Inc | 829.45m | -1.63m | 9.05bn | 711.00 | -- | 18.82 | 167.42 | 10.91 | -0.0644 | -0.0644 | 6.19 | 3.43 | 0.657 | -- | -- | 1,166,594.00 | 2.39 | -25.96 | 2.76 | -30.82 | -- | -- | 3.63 | -76.01 | -- | 1.89 | 0.5528 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| Tempus AI Inc | 1.11bn | -203.88m | 9.33bn | 2.40k | -- | 18.36 | -- | 8.44 | -1.18 | -1.18 | 6.45 | 2.86 | 0.6795 | 9.29 | 5.15 | 460,524.20 | -12.53 | -53.69 | -15.38 | -72.10 | 61.73 | 45.68 | -18.45 | -84.29 | 3.12 | -3.83 | 0.7104 | -- | 30.38 | 62.05 | -180.61 | -- | 5.36 | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 10.30bn | 3.10k | 129.76 | 5.11 | 56.08 | 8.48 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Summit Therapeutics Inc | 0.00 | -921.62m | 10.31bn | 159.00 | -- | 53.63 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2583 | 0.00 | -- | -- | 0.00 | -241.08 | -78.31 | -287.72 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Madrigal Pharmaceuticals Inc | 740.64m | -289.13m | 10.52bn | 528.00 | -- | 16.81 | -- | 14.21 | -13.01 | -13.01 | 33.39 | 27.56 | 0.6082 | 0.9008 | 10.30 | 1,402,727.00 | -23.74 | -68.48 | -30.98 | -85.32 | 95.25 | -- | -39.04 | -876.55 | 3.26 | -- | 0.3519 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| ICON PLC | 8.10bn | 599.48m | 11.10bn | 39.80k | 19.65 | 1.19 | 11.23 | 1.37 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Exelixis Inc | 2.29bn | 677.90m | 11.36bn | 1.15k | 17.84 | 5.26 | 16.05 | 4.96 | 2.38 | 2.38 | 8.00 | 8.06 | 0.7913 | 3.19 | 7.90 | 1,994,959.00 | 23.44 | 9.51 | 27.03 | 10.77 | 96.63 | 96.32 | 29.63 | 15.61 | 3.68 | -- | 0.00 | 0.00 | 18.49 | 17.51 | 150.89 | 10.18 | 17.25 | -- |
Data as of Feb 06 2026. Currency figures normalised to Charles River Laboratories International Inc's reporting currency: US Dollar USD
43.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.45m | 11.08% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.82m | 5.73% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 2.80m | 5.69% |
| Allspring Global Investments LLCas of 31 Dec 2025 | 1.97m | 4.00% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.83m | 3.72% |
| Ariel Investments LLCas of 30 Sep 2025 | 1.49m | 3.03% |
| Harris Associates LPas of 30 Sep 2025 | 1.47m | 2.99% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.27m | 2.57% |
| Invesco Capital Management LLCas of 30 Sep 2025 | 1.24m | 2.51% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 1.02m | 2.08% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
